Mary Anastasia O’Grady on Free Trade and Drug Prohibition in Latin America

The Mary Anastasia O‚ÄôGrady ‚Äì  longtime WSJ Americas columnist — is one of the most insightful commentators on Latin American politics and economics. In this ReasonTV interview, O‚ÄôGrady comments on the impact of free trade and drug prohibition on Latin America:

Our broken tax system

File this excellent Cato Institute video on our governments’ absurdly complicated tax system in the “why do we do this to ourselves” category of out-of-control governmental policies that include such intrusions as security theater and overcriminalization:

Malkiel on investing

Burton Malkiel’s WSJ op-ed yesterday on the importance of investing in China’s growth reminded me of this lengthy and engaging lecture that he gave earlier this year. It may take several sessions to get through the entire talk, but it’s definitely worth the effort.

Richard Epstein on Obama

Reason‘s Nick Gillespie recently interviewed Richard A. Epstein (previous posts here), who explains how misdirected governmental programs under both Republican and Democratic administrations are having a devastating impact on economic growth and prosperity.

The entire interview is well worth watching. However, the initial portion of it (excerpted below) is particularly interesting because Epstein passes along his personal observations about Barack Obama gained from his experiences with Obama while both served on the University of Chicago Law School faculty.

While certainly not as bad as this, Epstein’s portrayal of Obama is but not particularly reassuring, either.

200 Countries, 200 Years, 4 Minutes

Plotting life expectancy against income for 200 countries since 1810, Hans Rosling shows the enormous impact that the increase in wealth has had on the world (H/T Don Boudreaux).

America’s experiment with universal coverage

DIALYSIS 57X57Many folks believe that universal health insurance coverage is a panacea to the fractured U.S. health care finance system. But take a few minutes to read this masterful Robin Fields/Atlantic article on the unexpected consequences of the nearly universal coverage provided for kidney dialysis patients:

IN OCTOBER 1972, after a month of deliberation, Congress launched the nation’s most ambitious experiment in universal health care: a change to the Social Security Act that granted comprehensive coverage under Medicare to virtually anyone diagnosed with kidney failure, regardless of age or income.

It was a supremely hopeful moment. Although the technology to keep kidney patients alive through dialysis had arrived, it was still unattainable for all but a lucky few. At one hospital, a death panel-or “God committee” in the parlance of the time-was deciding who got it and who didn’t. The new program would help about 11,000 Americans for starters, and for a modest initial price tag of $135 million, would cover not only their dialysis and transplants, but all of their medical needs. Some consider it the closest that the United States has come to socialized medicine.

Now, almost four decades later, a program once envisioned as a model for a national health-care system has evolved into a hulking monster. Taxpayers spend more than $20 billion a year to care for those on dialysis-about $77,000 per patient, more, by some accounts, than any other nation. Yet the United States continues to have one of the industrialized world’s highest mortality rates for dialysis care. Even taking into account differences in patient characteristics, studies suggest that if our system performed as well as Italy’s, or France’s, or Japan’s, thousands fewer kidney patients would die each year.

In a country that regularly boasts about its superior medical system, such results might be cause for outrage. But although dialysis is a lifeline for almost 400,000 Americans, few outside this insular world have probed why a program with such compassionate aims produces such troubling outcomes. Even during a fervid national debate over health care, the state of dialysis garnered little public attention.

Yet another example of what  Arnold Kling has observed about U.S. health care — why do we think that that we cannot possibly afford high-quality health care if we have to pay for it individually, but we can afford it if we pay for it collectively?

Putting the Pencil to the Federal Budget

CalculatorSeveral days ago, I posted on Twitter about the NY Times federal budget calculator, which is receiving well-deserved praise around the blogosphere.

For example, economists such as Clear Thinkers favorites David Henderson and Arnold Kling  — as well as financial columnist James Pethokoukis — provide their views on what spending cuts to make in balancing the budget within a reasonable period of time without raising taxes.

As John Goodman points out, though, the elephant in the parlor in cutting the budget is how to corral Medicare costs without causing corresponding harm to the elderly. Details, details  .   .   .

Nevertheless, Professor Henderson sums up the importance of the calculator as an educational tool:

Here’s a prediction: if the New York Times keeps this game up on its site, a whole lot of people are going to be more sympathetic to cutting government and more optimistic that it can be done.

One of my objections to Tea Partiers is how uninformed some of them are about the numbers. Now, thanks to the New York Times, they don’t have to be.

An unintended consequence of Medicare

medicare2008A frequent topic on this blog has been the demise of primary care under our third-party payor-dominated health care finance system.  Richard M. Hannon, a Blue Cross-Blue Shield executive, provides a particularly lucid explanation in this recent WSJ op-ed on how one of the unintended consequences of Medicare was the negative impact it had on the delivery of primary care to patients:

Medicare introduced a whole new dynamic in the delivery of health care. Gone were the days when physicians were paid based on the value of their services. With payment coming directly from Medicare and the federal government, patients who used to pay the bill themselves no longer cared about the cost of services.

Eventually, that disconnect (and subsequent program expansions) resulted in significant strain on the federal budget. In 1966, the House Ways and Means Committee estimated that by 1990 the Medicare budget would quadruple to $12 billion from $3 billion. In fact, by 1990 it was $107 billion.

To fix the cost problem, Medicare in 1992 began using the "resource based relative value system" (RBRVS), a way of evaluating doctors based on factors such as education, effort and specialized training. But the system didn’t consider factors such as outcomes, quality of service, severity or demand.

Today most insurance companies use the Medicare RBRVS because it is perceived as objective. As a result of RBRVS, specialists-especially those who perform a lot of procedures-do extremely well. Primary-care doctors do not.

The primary-care doctor has become a piece-rate worker focused on the volume of patients seen every day. As Medicare and insurers focused on trimming the costs of the most common procedures, the income and job satisfaction of primary-care doctors eroded.

So these doctors left, sold or changed their practices. New health-care service models, such as the concierge practice and the Patient-Centered Medical Home, drew doctors away from the standard service models that most patients rely on for coverage.

All of these factors have contributed to a fragmented, expensive health system with most of the remaining doctors focused on reactive instead of preventive care.

The solution to the problem is making primary-care physicians the captains of the ship. They must have the time and financial resources necessary to take care of their patients, tailoring care to patients’ specific conditions and needs. And they need the data to track their patients’ results, so they can guide patient progress. They will then be able to slow (and sometimes reverse) their patients’ illnesses, keeping them out of hospital emergency rooms and specialists’ offices. The end result: reduced costs and improved quality of care.

So who really killed primary care? The idea that a centrally planned system with the right formulas and lots of data could replace the art of practicing medicine; that the human dynamics of market demand and the patient-physician relationship could be ignored. Politicians and mathematicians in ivory towers have placed primary care last in line for respect, resources and prestige-and we all paid an enormous price.

The pervasive effect of the now engrained third-party payor system of health care finance is that many patients do not feel any responsibility for their health care expenses.  As Arnold Kling has observed, why do we think that that we cannot possibly afford high-quality health care if we have to pay for it individually, but we can afford it if we pay for it collectively?

There is more than one way to skin a cat

legal-drugs At least that’s the case when it comes to getting around dubious drug prohibition policies. Check out this WSJ article:

When the housing market crashed in 2008, David Llewellyn’s construction business went with it. Casting around for a new gig, he decided to commercialize something he’d long done as a hobby: making drugs.

But the 49-year-old Scotsman didn’t go into the illegal drug trade. Instead, he entered the so-called "legal high" business-a burgeoning industry producing new psychoactive powders and pills that are marketed as "not for human consumption."

Mr. Llewellyn, a self-described former crack addict, started out making mephedrone, a stimulant also known as Meow Meow that was already popular with the European clubbing set. Once governments began banning it earlier this year, Mr. Llewellyn and a chemistry-savvy partner started selling something they dubbed Nopaine-a stimulant they concocted by tweaking the molecular structure of the attention-deficit drug Ritalin. [.  .  .]

Mr. Llewellyn is part of a wave of laboratory-adept European entrepreneurs who see gold in the gray zone between legal and illegal drugs. They pose a stiff challenge for European law-enforcement, which is struggling to keep up with all the new concoctions. Last year, 24 new "psychoactive substances" were identified in Europe, almost double the number reported in 2008,  .  .  .

Particularly interesting is Mr. Llewellyn’s “foolproof” safety testing method for new drugs:

[Mr. Llewellyn] boasts that his safety testing method is foolproof: He and several colleagues sit in a room and take a new product "almost to overdose levels" to see what happens. "We’ll all sit with a pen and a pad, some good music on, and one person who’s straight who’s watching everything," he says.